Last reviewed · How we verify
Bortezomib, Melphalan, Prednisone, Thalidomide
This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation.
This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation. Used for Multiple myeloma (newly diagnosed or relapsed/refractory).
At a glance
| Generic name | Bortezomib, Melphalan, Prednisone, Thalidomide |
|---|---|
| Also known as | Bortezomib, Velcade, Thalidomide |
| Sponsor | Fondazione EMN Italy Onlus |
| Drug class | Combination chemotherapy and immunomodulatory therapy |
| Target | Proteasome (bortezomib), DNA (melphalan), glucocorticoid receptor (prednisone), cereblon (thalidomide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bortezomib is a proteasome inhibitor that blocks NF-κB signaling and triggers apoptosis in myeloma cells. Melphalan is an alkylating agent causing DNA damage. Prednisone is a corticosteroid with immunosuppressive and anti-inflammatory effects. Thalidomide is an immunomodulatory agent that enhances cereblon-mediated degradation of IKZF1 and IKZF3, promoting anti-myeloma activity. Together, these agents provide synergistic cytotoxic and immunomodulatory effects.
Approved indications
- Multiple myeloma (newly diagnosed or relapsed/refractory)
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Anemia
- Infection
- Nausea/vomiting
- Constipation
- Fatigue
- Venous thromboembolism
Key clinical trials
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (PHASE1)
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients (PHASE3)
- Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone (PHASE3)
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma (PHASE4)
- GEM05 for Patients With Multiple Myeloma More Than 65 Years Old (PHASE3)
- GEM05 for Patients With Multiple Myeloma Under 65 Years (PHASE3)
- VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates (PHASE2)
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: